Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRIX |
---|---|---|
09:32 ET | 4246 | 15.985 |
09:34 ET | 6064 | 15.97 |
09:36 ET | 7203 | 16.01 |
09:38 ET | 657 | 16.09 |
09:39 ET | 100 | 16.105 |
09:41 ET | 348 | 16.1 |
09:43 ET | 300 | 16.07 |
09:45 ET | 908 | 16.18 |
09:50 ET | 1100 | 16.1 |
09:52 ET | 200 | 16.09 |
09:54 ET | 400 | 16.07 |
09:57 ET | 300 | 16.04 |
09:59 ET | 100 | 16.09 |
10:01 ET | 200 | 16.11 |
10:03 ET | 300 | 16.115 |
10:06 ET | 800 | 16.145 |
10:12 ET | 400 | 16.1 |
10:14 ET | 485 | 16.06 |
10:21 ET | 100 | 16.09 |
10:24 ET | 800 | 16.125 |
10:26 ET | 100 | 16.1 |
10:28 ET | 1200 | 16.06 |
10:30 ET | 200 | 16.105 |
10:37 ET | 600 | 16.13 |
10:42 ET | 8200 | 16.21 |
10:44 ET | 900 | 16.21 |
10:46 ET | 600 | 16.25 |
10:48 ET | 200 | 16.3 |
10:50 ET | 409 | 16.28 |
10:51 ET | 511 | 16.225 |
10:53 ET | 100 | 16.24 |
10:57 ET | 600 | 16.18 |
11:00 ET | 202 | 16.1301 |
11:02 ET | 600 | 16.15 |
11:04 ET | 300 | 16.205 |
11:08 ET | 700 | 16.17 |
11:11 ET | 500 | 16.15 |
11:13 ET | 200 | 16.17 |
11:15 ET | 636 | 16.16 |
11:18 ET | 493 | 16.15 |
11:20 ET | 149 | 16.135 |
11:22 ET | 249 | 16.14 |
11:24 ET | 400 | 16.15 |
11:26 ET | 400 | 16.17 |
11:27 ET | 300 | 16.19 |
11:33 ET | 100 | 16.195 |
11:38 ET | 500 | 16.1956 |
11:40 ET | 1500 | 16.27 |
11:42 ET | 837 | 16.29 |
11:44 ET | 200 | 16.32 |
11:45 ET | 3817 | 16.26 |
11:47 ET | 100 | 16.25 |
11:49 ET | 600 | 16.25 |
11:51 ET | 100 | 16.22 |
11:54 ET | 400 | 16.18 |
11:58 ET | 571 | 16.2 |
12:02 ET | 200 | 16.12 |
12:05 ET | 100 | 16.13 |
12:07 ET | 800 | 16.15 |
12:12 ET | 1047 | 16.13 |
12:14 ET | 100 | 16.07 |
12:16 ET | 100 | 16.06 |
12:18 ET | 700 | 16.09 |
12:20 ET | 800 | 16.05 |
12:25 ET | 552 | 16.1 |
12:27 ET | 1000 | 16.115 |
12:30 ET | 600 | 16.09 |
12:32 ET | 500 | 16.11 |
12:34 ET | 600 | 16.04 |
12:36 ET | 181 | 16.0012 |
12:41 ET | 600 | 16.02 |
12:43 ET | 116 | 16.01 |
12:48 ET | 700 | 16.015 |
12:54 ET | 120 | 16.0108 |
12:56 ET | 100 | 16.02 |
01:01 ET | 1302 | 16.01 |
01:03 ET | 100 | 16.01 |
01:12 ET | 312 | 15.99 |
01:15 ET | 100 | 15.98 |
01:19 ET | 228 | 15.95 |
01:24 ET | 200 | 15.95 |
01:26 ET | 100 | 15.93 |
01:28 ET | 100 | 15.93 |
01:32 ET | 438 | 15.88 |
01:33 ET | 299 | 15.87 |
01:35 ET | 100 | 15.85 |
01:42 ET | 600 | 15.87 |
01:46 ET | 100 | 15.85 |
01:48 ET | 200 | 15.87 |
01:50 ET | 300 | 15.85 |
01:51 ET | 300 | 15.85 |
01:53 ET | 100 | 15.83 |
01:55 ET | 100 | 15.83 |
01:57 ET | 300 | 15.84 |
02:00 ET | 400 | 15.835 |
02:02 ET | 438 | 15.755 |
02:06 ET | 1256 | 15.73 |
02:08 ET | 500 | 15.73 |
02:09 ET | 900 | 15.74 |
02:13 ET | 500 | 15.705 |
02:15 ET | 200 | 15.71 |
02:20 ET | 1700 | 15.718 |
02:22 ET | 900 | 15.75 |
02:29 ET | 300 | 15.74 |
02:31 ET | 100 | 15.73 |
02:40 ET | 300 | 15.755 |
02:42 ET | 300 | 15.805 |
02:44 ET | 500 | 15.79 |
02:45 ET | 200 | 15.79 |
02:49 ET | 800 | 15.84 |
02:51 ET | 3216 | 15.8732 |
02:56 ET | 100 | 15.86 |
02:58 ET | 1000 | 15.82 |
03:03 ET | 200 | 15.84 |
03:05 ET | 100 | 15.85 |
03:09 ET | 200 | 15.83 |
03:12 ET | 491 | 15.81 |
03:14 ET | 403 | 15.79 |
03:16 ET | 200 | 15.825 |
03:18 ET | 1200 | 15.83 |
03:20 ET | 500 | 15.79 |
03:21 ET | 300 | 15.7673 |
03:23 ET | 1621 | 15.76 |
03:25 ET | 600 | 15.805 |
03:27 ET | 100 | 15.815 |
03:30 ET | 100 | 15.82 |
03:32 ET | 1344 | 15.85 |
03:34 ET | 100 | 15.84 |
03:36 ET | 300 | 15.83 |
03:38 ET | 500 | 15.87 |
03:39 ET | 300 | 15.88 |
03:43 ET | 1300 | 15.9 |
03:45 ET | 3419 | 15.9 |
03:48 ET | 1100 | 15.87 |
03:52 ET | 912 | 15.92 |
03:54 ET | 2099 | 15.83 |
03:56 ET | 7255 | 15.72 |
03:57 ET | 7531 | 15.66 |
03:59 ET | 101190 | 15.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nurix Therapeutics Inc | 945.9M | -5.9x | --- |
CureVac NV | 906.2M | -3.4x | --- |
Arcutis Biotherapeutics Inc | 912.2M | -2.5x | --- |
Gyre Therapeutics Inc | 930.4M | -5.9x | --- |
Regenxbio Inc | 705.3M | -2.4x | --- |
Prothena Corporation PLC | 1.2B | -6.5x | --- |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $999.9M |
---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.17 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 12.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.